Publikationen in Zusammenarbeit mit Forschern von University of Paris-Sorbonne (100)

2024

  1. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

  2. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

    CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

  3. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

  4. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

    Human Genetics and Genomics Advances, Vol. 5, Núm. 3

  6. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

    Ophthalmic research, Vol. 67, Núm. 1, pp. 311-321

  7. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  8. Predictors of pulmonary embolism in chronic obstructive pulmonary diseases patients admitted for worsening respiratory symptoms: An individual participant data meta-analyses

    European Journal of Internal Medicine

  9. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes

    Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1796-1802

  10. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

  11. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  12. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

    Breast, Vol. 78

  13. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

  14. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

  15. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

    Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973

  16. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  3. Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies

    Journal of the American Heart Association, Vol. 12, Núm. 12, pp. e027657

  4. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393